胰高血糖素样肽-1受体作为新兴靶点:能否进入临床?
本文综述胰高血糖素样肽-1受体(GLP-1R)靶向影像在良性胰岛素瘤及胰岛细胞增生症定位中的应用进展。自2008年首次用111In-DTPA-exendin-4在人体定位隐匿性胰岛素瘤后,多种GLP-1R PET/CT显像剂被合成并评估;前瞻性对比研究显示GLP-1R PET/CT对良性胰岛素瘤的检出敏感性显著高于增强MRI、增强CT、GLP-1R SPECT/CT及生长抑素受体PET/CT,欧洲神经内分泌肿瘤学会指南已推荐在ceMRI/ceCT或超声内镜阴性但临床怀疑胰岛素瘤的患者中行GLP-1R显像或ASVS。
要点
- GLP-1R PET/CT对良性胰岛素瘤的检出敏感性显著高于ceMRI、ceCT及生长抑素受体PET/CT。
- ENETS指南推荐ceMRI/ceCT或EUS阴性但临床怀疑胰岛素瘤者行GLP-1R显像或ASVS。
- GLP-1R PET/CT可显示并定位成人胰岛细胞增生症,有助于区分局灶性与弥漫性病变。
核心结论
- GLP-1R靶向影像在良性胰岛素瘤和胰岛细胞增生症定位中具有临床相关性,常为唯一能定位病变的影像手段,并可能取代有创的ASVS定位。
- GLP-1R PET/CT对良性胰岛素瘤及MEN1相关胰岛素瘤的检出敏感性显著高于ceMRI、ceCT、GLP-1R SPECT/CT和生长抑素受体PET/CT。
研究设计与样本
- 综述类文章,未报告系统检索范围与样本量。
主要发现
- 2008年首次使用代谢稳定的放射性标记GLP-1激动剂111In-DTPA-exendin-4在人体定位隐匿性胰岛素瘤。
- 后续合成并评估了68Ga-DOTA-exendin-4、68Ga-NOTA-exendin-4和68Ga-NODAGA-exendin-4等GLP-1R PET/CT显像剂。
- 多项前瞻性对比研究显示GLP-1R PET/CT对良性胰岛素瘤及MEN1相关胰岛素瘤的检出敏感性显著高于ceMRI、ceCT、GLP-1R SPECT/CT和生长抑素受体PET/CT。
- 越来越多证据表明GLP-1R PET/CT可显示并定位成人胰岛细胞增生症,区分局灶性与弥漫性对治疗策略至关重要。
- 前瞻性研究证明GLP-1R显像常为唯一能定位胰岛素瘤或胰岛细胞增生症的影像手段。
关键数值与推荐
- 欧洲神经内分泌肿瘤学会指南推荐:临床怀疑胰岛素瘤但ceMRI/ceCT或超声内镜阴性的患者,可行GLP-1R显像或选择性动脉内钙刺激静脉采血(ASVS)。
临床怎么用
- 对临床怀疑胰岛素瘤而ceMRI/ceCT或EUS阴性的患者,可行GLP-1R PET/CT定位,常为唯一能定位病变的影像手段。
- GLP-1R PET/CT可区分局灶性与弥漫性胰岛细胞增生症,指导治疗策略。
- GLP-1R显像有望替代有创的ASVS用于胰岛素瘤定位。
局限性
- 本文为综述,未报告系统检索范围,所引前瞻性研究的样本量未在原文中给出。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The glucagon-like peptide-1 receptor (GLP-1R) is an emerging target due to its high expression in benign insulinomas as well as in islet cell hypertrophia/hyperplasia (nesidioblastosis) and pancreatic β-cells. In 2008, occult insulinomas were localized for the first time in men using the metabolically stable radiolabeled glucagon-like peptide-1 (GLP-1) agonist [Lys40(Ahx-DTPA-111In)NH2]-exendin-4 (111In-DTPA-exendin-4). Afterward, several radiopharmaceuticals for GLP-1R PET/CT imaging were synthesized and evaluated, for example, [Nle14,Lys40(Ahx-DOTA-68Ga)NH2]-exendin-4 (68Ga-DOTA-exendin-4), [Cys40(MAL-NOTA-68Ga)NH2]-exendin-4 (68Ga-NOTA-exendin-4), and [Lys40(NODAGA-68Ga)NH2]-exendin-4 (68Ga-NODAGA-exendin-4). Several prospective comparison studies provided evidence that GLP-1R PET/CT is significantly more sensitive than contrast-enhanced MRI (ceMRI), contrast-enhanced CT (ceCT), GLP-1R SPECT/CT, somatostatin receptor PET/CT, and SPECT/CT in the detection of benign insulinomas, and insulinomas in the context of multiple endocrine neoplasia type 1. As a result, the European Neuroendocrine Tumor Society guidelines recommend GLP-1R imaging or selective intraarterial calcium stimulation and venous sampling (ASVS) in patients for whom there is a clinical suspicion of having an insulinoma but who have a negative ceMRI/ceCT or negative endoscopic ultrasound. Furthermore, there is growing evidence that GLP-1R PET/CT can visualize and localize adult nesidioblastosis. This is clinically relevant as the distinction between focal and diffuse nesidioblastosis is critical in directing a therapeutic strategy in these patients. Prospective studies have proven the clinical relevance of GLP-1R imaging as it is often the only imaging modality able to localize the insulinoma or nesidioblastosis. It is therefore likely that this noninvasive imaging modality will replace the invasive localization of insulinomas using ASVS. More experimental indications for GLP-1R imaging include the diagnosis of an insulinoma/nesidioblastosis in patients with postprandial hypoglycemia after bariatric bypass surgery and monitoring β-cells in patients with brittle type 1 diabetes after islet-cell transplantation. We believe that these indications and possibly future indications will bring GLP-1R imaging to the clinic.
引用
- Wild D, Antwi K, Fani M, et al. Glucagon-like Peptide-1 Receptor as Emerging Target: Will It Make It to the Clinic? J Nucl Med. 2021. PMID: 34230073. doi:10.2967/jnumed.120.246009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。